ÇÏÁ¾¿ø ¸íÀÇ

ÀÌ½Ä ¹ÞÀº Àå±â ÃÖ´ëÇÑ ¿À·¡ À¯Áö½ÃŲ´Ù

ÇÏÁ¾¿ø ¸íÀÇ

  • ¼Ò ¼Ó
    ¼­¿ï´ëº´¿ø ¿Ü°ú
  • Àü¹®ºÐ¾ß
    ÃéÀåÀ̽Ä, Ç÷ÀüÁõ, ÇÏÁöÁ¤¸Æ·ù, ½ÅÀåÀ̽Ä

ÁÖ¿ä Áø·á ºÐ¾ß´Â ½ÅÀåÀ̽Ä, ÃéÀåÀ̽Ä, º¹ºÎ ¹× ÇÏÁöµ¿¸Æ Áúȯ, ÇÏÁöÁ¤¸Æ·ùÀÌ´Ù.
ƯÈ÷ À̽ÄȯÀÚÀÇ ¸é¿ª¾ïÁ¦ Ä¡·á ºÐ¾ß¿¡¼­ ¸í¼ºÀÌ ³ô´Ù. ¸é¿ª¾ïÁ¦¿Í °ü·ÃÇÑ À¯ÀüÀÚ ¿¬±¸¸¦ ÅëÇØ ÀÌ½Ä Àå±â¸¦ ÃÖ´ëÇÑ ¿À·¡ ¾µ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ °ü½ÉÀÌ ¸¹´Ù. ½ÅÀåÀ» ÀÌ½Ä ¹ÞÀº ¼Ò¾Æ ȯÀÚµéÀÌ ¸é¿ª¾ïÁ¦Á¦¸¦ ÇÏ·ç¿¡ ÇÑ ¹ø¸¸ ¸Ô¾îµµ °ÅºÎ¹ÝÀÀ ¾øÀÌ »ýȰÇÒ ¼ö ÀÖ´Ù´Â ¿¬±¸ °á°ú¸¦ ¹ßÇ¥Çϱ⵵ Çß´Ù. CJ±×·ì ÀÌÀçÇö ȸÀåÀÇ ½ÅÀåÀ̽ÄÀ» ÁýµµÇÑ ÀÇ»ç·Îµµ ¾Ë·ÁÁ³´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ëÇб³ Àǰú´ëÇпø ÀÇÇйڻç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇпø ÀÇÇм®»ç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ¼­¿ï´ëÇб³º´¿ø Àå±âÀ̽ļ¾ÅͼÒÀå
  • ¹Ì±¹ ¿¡¸ð¸®´ëÇÐ ÃéµµÀÌ½Ä½Ç ¹æ¹®±³¼ö (2004)
  • ¹Ì±¹ ¿¡¸ð¸®´ëÇÐ À̽ĸ鿪ÇÐ ¹æ¹®±³¼ö (1998 ~ 2000)

ÇÐȸȰµ¿

Academic activities
  • 2019.10 ~ 2021.10´ëÇÑÀ̽ÄÇÐȸ ÀÌ»çÀå
  • 2011.03 ~ 2016.03Çѱ¹Àå±â±âÁõ¿ø ÀÌ»çÀå
  • 2009.02 ~ 2011.03º¸°Çº¹Áö°¡Á·ºÎ Áö¿ø µ¶¸³Àå±â±¸µæ±â°ü ¼³¸³Ã¥ÀÓÀÚ
  • 2007.04 ~ 2018.02¼­¿ï´ëÇб³º´¿ø ¿Ü°ú À̽ÄÇ÷°ü¿Ü°ú ºÐ°úÀå
  • ´ëÇÑÀ̽ÄÇÐȸ / ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ / ´ëÇÑÁ¤¸ÆÇÐȸ / ´ëÇѿܰúÇÐȸ
  • Asian society of transplantation
  • International xenotransplantation association
  • American society of transplantation
  • The Transplantation Society
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients.
¹ßÇ¥³âµµ 2013 ¹ßÇ¥Áö Nephrol Dial Transplant
Á¦ ¸ñ Outcomes of kidney allograft in recipients with kidney disease of unknown etiology.
¹ßÇ¥³âµµ 2013 ¹ßÇ¥Áö Clin Transplant
Á¦ ¸ñ Beneficial effects of pretransplantation microchimerism on rejection-free survival in HLA-haploidentical family donor renal transplantation.
¹ßÇ¥³âµµ 2013 ¹ßÇ¥Áö Transplantation
Á¦ ¸ñ Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy.
¹ßÇ¥³âµµ 2013 ¹ßÇ¥Áö Am J Transplant
Á¦ ¸ñ Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
¹ßÇ¥³âµµ 2012 ¹ßÇ¥Áö Ther Drug Monit
Á¦ ¸ñ Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
¹ßÇ¥³âµµ 2013 ¹ßÇ¥Áö Eur J Clin Pharmacol
Á¦ ¸ñ Cold ischemic time is critical in outcomes of expanded criteria donor renal transplantation
¹ßÇ¥³âµµ 2013 ¹ßÇ¥Áö Clin Transplant

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

¼­¿ï´ëº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-5700
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

¼­¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼­ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ­¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.

¼­¿ï´ëº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä